All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Proteona

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Singapore

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Proteona’s ESCAPE™ platform selected for SARS-CoV-2 vaccine characterization

Lead Product(s): SARS-CoV-2 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Flinders University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 12, 2020

Details:

Proteona will use its ESCAPE™ technology to profile the immune response of patients receiving the vaccine. The technology will be used by Professor Petrovsky to characterize the clinical response to a new SARS-CoV-2 vaccine which is under investigation.